Alliance Steering Committee Sample Clauses

Alliance Steering Committee. 2 1.3 ASTA Medica Improvements..................................................................... 2 1.4 ASTA Medica Know-How......................................................................... 2 1.5 ASTA Medica Patent Rights.................................................................... 2 1.6
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Alliance Steering Committee. Commencing on the Effective Date of the Fourth Amendment, the strategic direction of the collaboration between the Parties under this Agreement and the Co-Promotion Agreement shall be managed by, and all disputes arising under this Agreement shall be submitted for attempted resolution to, a committee known as the “Alliance Steering Committee” or “ASC”. The ASC shall consist of two members, the Chief Executive Officer of Onyx and the Chief Executive Officer of Bayer HealthCare AG, who shall serve as joint chairs of the ASC. The ASC shall meet and attempt in good faith to promptly resolve all disputes arising under this Agreement as described in Article 25. In addition to such meetings, the ASC shall meet at least once per Contract Year in late June or early July to discuss and agree upon the strategic direction and priorities of the Parties’ efforts pursuant to this Agreement and the Co-Promotion Agreement. The ASC shall strive to operate by consensus, provided that in the event of a dispute between the members of the ASC, either member of the ASC may refer such dispute to arbitration in accordance with Section 25.1. Notice of such meetings shall be given 30 days in advance to each member, stating the date, time and place of such meeting and describing the proposed agenda of items to be discussed at such meeting. Either Party may place items on the proposed agenda. Responsibility for arranging meetings will alternate between the Parties, with Onyx having responsibility for the first meeting, and either Party may invite other employees to participate in such meetings (which individuals will not be included in the determination for consensus of the ASC), provided that an executive session comprised of only the two members of the ASC shall be required. The ASC may conduct meetings in person or by telephone, video or Internet-enabled conference, provided that at least one strategic meeting (as opposed to those dispute resolution meetings held pursuant to Article 25) per Contract Year shall be held in person. The ASC shall keep minutes reflecting actions taken at meetings, which minutes shall be reviewed and approved by both members within 10 days after the applicable meeting and shall be promptly distributed to all members of the EC. The ASC may act without a meeting if prior to such action a written consent thereto is signed by both members. The ASC may amend or expand upon the foregoing procedures for its internal operation by unanimous written consent.
Sample 1Sample 2
Alliance Steering Committee. The selection of Alliance Steering Committee members shall be made by ASTA-Medica and BioNumerik Pharmaceuticals, Inc. as needed from time to time. The Alliance Steering Committee members shall be qualified representatives of each company with expertise in oncology drug development and commercialization operations. The Alliance Steering Committee will be comprised of an equal number of members from ASTA Medica and BioNumerik, provided however, that each Party must have on the Alliance Steering Committee employees holding the following positions: Head of Research and Development and Head of Sales and Marketing. On behalf of BioNumerik, Xx. Xxxxxxxx will communicate strategies, developments and operations relating to the Product(s) to the Alliance Steering Committee.
Sample 1Sample 2
Alliance Steering Committee. The Parties shall maintain an Alliance steering committee (the “Alliance Steering Committee”) consisting of six (6) members, three (3) of which shall be appointed by Xxxxxx and three (3) of which shall be appointed by HGTY. Any member of the Alliance Steering Committee may be removed and replaced with a newly appointed individual by the Party who appointed such member at any time upon written notice to the other Party.
Sample 1
Alliance Steering Committee. Commencing on the Effective Date, the strategic direction of the collaboration between the Parties under this Agreement shall be managed by, and all disputes arising under this Agreement shall be submitted for attempted resolution to the ASC. The ASC shall meet and attempt in good faith to promptly resolve all disputes arising under this Agreement as described in Article 11. In addition to such meetings, the ASC shall meet at least once per Contract Year in late June or early July to discuss and agree upon the strategic direction and priorities of the Parties’ efforts pursuant to this Agreement. The ASC shall operate by consensus and pursuant to the procedures described in the Collaboration Agreement.
Sample 1
Alliance Steering Committee 
Sample 1Sample 2Sample 3

Related to Alliance Steering Committee

  • Steering Committee The Project Manager shall set up a Steering Committee for the Project, consisting of representatives from the Department, the Contractor, and any other key organisations whom the project will impact on, to be agreed between the parties. The function of the Steering Committee shall be to review the scope and direction of the Project against its aims and objectives, monitor progress and efficiency, and assess, manage and review expected impact and use of the findings from the Project. The Committee shall meet at times and dates agreed by the parties, or in the absence of agreement, specified by the Department. The Contractor’s representatives on the Steering Committee shall report their views on the progress of the Project to the Steering Committee in writing if requested by the Department. The Contractor’s representatives on the Steering Committee shall attend all meetings of the Steering Committee unless otherwise agreed by the Department.

  • Joint Steering Committee [***] following the Effective Date [***], a joint steering committee (the “JSC”) will be established by the Parties to provide oversight and to facilitate information sharing between the Parties with respect to the activities under this Agreement.

  • Development Committee As soon as practicable, the Parties will establish a joint development committee, comprised of at least one (1) and up to two (2) representatives of Omega and at least one (1) and up to two (2) representatives of Acuitas (the “JDC”). One such representative from each Party will be such Party’s Workplan Leader. Each Party may replace its Workplan Leader and other JDC representatives at any time upon written notice to the other Party, provided, however, that each Party shall use reasonable efforts to ensure continuity on the JDC. With the consent of the other Party (which will not be unreasonably withheld, conditioned or delayed), each Party may invite non-voting employees and consultants to attend JDC meetings as necessary, subject to consultant’s agreement to be bound to the same extent as a permitted subcontractor under Section 3.1(i).

  • Research Committee 2.2.1 Establishment and Functions of RC. ---------------------------------

  • Joint Research Committee The Parties hereby establish a committee to facilitate the Research Program as follows:

  • Operating Committee the Consortium’s managing body, composed of representatives of the Manager and the Contractors, pursuant to Annex XI.

  • Joint Development Committee The Parties shall form a joint development committee (the “Joint Development Committee” or “JDC”), made up of an equal number of representatives of Merck and BioLineRx, which shall have responsibility of coordinating all regulatory and other activities under, and pursuant to, this Agreement. Each Party shall designate a project manager (the “Project Manager”) who shall be responsible for implementing and coordinating activities, and facilitating the exchange of information between the Parties, with respect to the Study. Other JDC members will be agreed by both Parties. The JDC shall meet as soon as practicable after the Effective Date and then no less than twice yearly, and more often as reasonably considered necessary at the request of either Party, to provide an update on the progress of the Study. The JDC may meet in person or by means of teleconference, Internet conference, videoconference or other similar communications equipment. Prior to any such meeting, the BioLineRx Project Manager shall provide an update in writing to the Merck Project Manager, which update shall contain information about the overall progress of the Study, recruitment status, interim analysis (if results available), final analysis and other information relevant to the conduct of the Study. In addition to a Project Manager, each Party shall designate an alliance manager (the “Alliance Manager”), who shall endeavor to ensure clear and responsive communication between the Parties and the effective exchange of information, and shall serve as the primary point of contact for any issues arising under this Agreement. The Alliance Managers shall have the right to attend all JDC meetings and may bring to the attention of the JDC any matters or issues either of them reasonably believes should be discussed, and shall have such other responsibilities as the Parties may mutually agree in writing. In the event that an issue arises and the Alliance Managers cannot or do not, after good faith efforts, reach agreement on such issue, the issue shall be elevated to the Head of Clinical Oncology for Merck and the Vice President of Medical Affairs or Business Development for BioLineRx.

  • Joint Manufacturing Committee In accordance with Section 2.5(c)(iv), the Parties shall promptly establish and convene a joint Manufacturing Committee (the “JMC”) for the overall coordination and oversight of the Manufacturing of clinical and commercial supplies of the Product under this Agreement as provided in the Manufacturing Plan (including the Manufacture of API, Drug Product and Finished Product). The JMC shall consist of representatives of each Party, and shall operate by procedures, as set forth in Section 2.5. The role of the JMC shall be:

  • Advisory Committee The Settling State shall designate an Opioid Settlement Remediation Advisory Committee (the “Advisory Committee”) to provide input and recommendations regarding remediation spending from that Settling State’s Abatement Accounts Fund. A Settling State may elect to use an existing advisory committee or similar entity (created outside of a State-Subdivision Agreement or Allocation Statute); provided, however, the Advisory Committee or similar entity shall meet the following requirements:

  • Alliance Managers In addition to the foregoing governance provisions, each of the Parties shall appoint a single individual to serve as that Party’s alliance manager (“Alliance Manager”). The role of each Alliance Manager will be to participate and otherwise facilitate the relationship between the Parties as established by this Agreement. A Party may replace its Alliance Manager from time to time upon written notice to the other Party.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!